REVIEWVitamin K deficiency bleeding (VKDB) in early infancy
Introduction
The first description of a coagulopathy that had all the attributes of severe vitamin K (VK) deficiency is accredited to a Boston physician, Charles Townsend who in 1894 described 50 cases of a generalized bleeding tendency in neonates, which he thought sufficiently similar to classify as a single entity and which he named the Haemorrhagic Disease of the Newborn (HDN).1 Townsend noted that HDN could be differentiated from haemophilia by its much earlier time of presentation (usually on days 2 to 3), lack of family history and by its self-limiting time course. Commenting on the complete recovery of one particular 9-day old infant with presumed meningeal haemorrhage, considered by the first physician to be a ‘bleeder’ (haemophiliac) and a hopeless case, Townsend noted “The belief that the disease was self-limited, with careful artificial and wet nurse feeding, the mother’s supply proving a failure, was what saved the baby”. Thus Townsend made the first recorded link between the mother’s capacity to breast-feed and the haemostatic capacity of her newborn infant.1 The fascinating history of VKDB in infancy has been reviewed by Hathaway,2 a history that is littered with uncertainties and controversies on the extent of the problem and the role of VK prophylaxis in public health that still persist to the present day.
The name change from HDN to vitamin K deficiency bleeding (VKDB) was recommended by the ISTH Pediatric/Perinatal Subcommittee in 1999 to clarify that the etiological basis was solely due to VK-deficiency and to include those infants who develop VKDB beyond the usually defined 4-week neonatal period.3 Finally, the new name avoids any possible confusion of HDN with haemolytic disease of the newborn. Though VKDB is rare in most developed countries, the consequences for the few who develop it are potentially catastrophic with over 50% of infants with late VKDB (post 1-week) presenting with intracranial haemorrhage (ICH).4 For this reason nearly all developed countries have introduced prophylactic measures for its prevention. The inability to identify infants at risk has meant that prophylaxis is either given to all newborns or to those whose mothers intend to exclusively breast-feed them. Protection of breast-fed infants is important because VKDB is strongly associated with breast-feeding and is rare in formula-fed infants. A few countries such as the UK, Germany and the Netherlands have surveillance schemes in place to monitor the effectiveness of VK prophylaxis.
The classical role of VK is as an anti-haemorrhagic factor that is needed for the synthesis in the liver of functional forms of prothrombin (factor II) together with factors VII, IX and X.5 After secretion into the blood, these four VK-dependent proteins become available to take part in blood coagulation, the complex series of events that, once initiated, culminates in the conversion of fibrinogen to fibrin and the formation of a haemostatic plug. The biochemical role of VK is to act as a cofactor for the conversion of specific peptide-bound glutamate (Glu) residues to γ-carboxyglutamate (Gla) residues. Hence VK-dependent proteins are often known as Gla-proteins. Two other Gla-proteins, proteins C and S, have well-defined roles in the negative feedback control of coagulation. Put simply, a deficiency of VK is a failure to synthesize γ-carboxyglutamic acid. The consequences of VK-deficiency for haemostasis are an inability to synthesize functional molecules of factors II, VII, IX and X resulting in a hypocoagulable state. The haemostatic system has a considerable capacity to function adequately at low-factor concentrations but as deficiency progresses a point will be reached when the procoagulatory mechanisms fail and bleeding occurs. This point is highly individual and unpredictable.
Section snippets
Nutrition and physiology of vitamin K in the healthy infant
Naturally occurring compounds with VK activity have a common 2-methyl-1,4-naphthoquinone nucleus and a variable alkyl substituent at the 3 position. The VK found in the plant kingdom is phylloquinone (vitamin K1) whereas the multiple forms of VK synthesized by bacteria are menaquinones (vitamins K2). Phylloquinone has a phytyl side chain whereas menaquinones have multi-prenyl side chains, the number of prenyl units being indicated by a suffix (i.e. menaquinone-n, abbreviated MK-n). In the
Classification and etiology of VKDB
In 1985, Lane and Hathaway27 gave a detailed description of three patterns of VKDB (Table 2), which is still widely accepted and recognized by the Pediatric/Perinatal Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH).3 It has been customary to differentiate between idiopathic and secondary VKDB. In secondary VKDB there is an underlying cause, usually an undiagnosed disease such as a hereditary hepatobiliary/malabsorptive disease (e.g. biliary atresia,
Clinical presentation
Early VKDB is rare but frequently life threatening. Common sites/bleed types are the head (cephalhaematoma, intracranial or at site of scalp electrodes), intrathoracic, intra-abdominal or gastrointestinal tract.27 The severity may relate to maternal drugs that inhibit VK metabolism. Idiopathic cases are rarer and sometimes the separation of early and classical VKDB as separate entities seems unwarranted. In a hospital-based Ethiopian survey of VKDB during the first week of life, the mean age of
Incidence of classical VKDB
There is little accurate national data on the incidence of classical VKDB, even in industrialized countries. In a two-year prospective survey in the British Isles56 during 1988–1990 the incidence rate of 5.4 per 105 births for classical VKDB57 was similar to that of 4.4 per 105 births for late VKDB.57 Earlier studies had suggested a higher incidence for classical VKDB with Salomonsen6 reporting that the incidence of classical VKDB in Oslo during 1934–1939 was 0.8%. The later important and
The vitamin K and childhood cancer story
The events that led to the ‘vitamin K and childhood cancer’ scare are a typically British story. On August 2nd 1990 the Guardian newspaper reported on an epidemiological study of Jean Golding and colleagues into factors associated with childhood cancer and particularly on an unexpected association with VK, which in the investigators words, ‘fitted no prior hypothesis’.73 The Guardian was the only paper to give this report any prominence; the article itself being a fair synopsis of Golding’s
Global perspectives of VKDB
While VKDB and its prevention is still a significant concern in industrialized countries, it is a bigger problem in emerging countries. In many low-income countries the problem is unseen or overshadowed by more common and more visible deprivation and disease. One reason for the lack of information from developing countries is that bleeding in infancy can have different causes and VKDB can only be properly diagnosed by laboratory tests or, failing this, by showing that bleeding responds to VK.
Practice points
- •
Late VKDB that presents as intracranial bleeding is often preceded by warning bleeds or bruising that should always be investigated by appropriate laboratory tests.
- •
Accurate diagnosis of VKDB requires that gestational and/or post-natal age be taken into consideration when interpreting coagulation results (developmental haemostasis).
- •
In cases of suspected VKDB confidence in diagnosis is greatly increased by use of specific tests of VK status (e.g. PIVKA-II) even post-VK or factor replacement.
- •
Research agenda
- •
Determine the bioavailability of low-dose oral drop regimens when taken with and without feeds.
- •
Make further use of local and national registries of diseases associated with cholestasis (e.g. biliary atresia and α-1-antitrypsin deficiency, cystic fibrosis) to assess prophylactic efficacy of different oral VK regimens.
- •
Incidence, causes, and prevention of VKDB in developing countries.
- •
Metabolism and dietary requirements of VK in infants during the first six months of life.
- •
Significance of gut
Conflict of interest statement
The author has previously received funding from F. Hoffmann-La-Roche Ltd., Basel, Switzerland for analytical work connected with the licensing of Konakion MM and a grant for the development of a PIVKA-II assay.
Acknowledgments
I would like to thank Dr. Paul Clarke, Norfolk and Norwich University Hospital for his thoughtful and incisive comments.
References (86)
- et al.
The content of phylloquinone (vitamin K1) in human milk, cows’ milk and infant formula foods determined by high-performance liquid chromatography
J Nutr
(1982) Vitamin K and human nutrition
J Am Diet Assoc
(1992)- et al.
Effect of vitamin K administration on acarboxy prothrombin (PIVKA-II) levels in newborns
Lancet
(1985) - et al.
Vitamin K concentrations in the plasma and liver of surgical patients
Am J Clin Nutr
(1990) The relevance of developmental hemostasis to hemorrhagic disorders of newborns
Semin Perinatol
(1997)- et al.
Coagulation changes in the neonatal period and in early infancy
Pediatr Clin North Am
(1962) - et al.
Heparin-like inhibitor, not vitamin K deficiency, in the newborn
Lancet (letter)
(1977) Vitamin K metabolism and nutriture
Blood Reviews
(1992)- et al.
Vitamin K in infancy
J Pediatr
(1985) - et al.
Haemorrhagic disease of the newborn returns
Lancet
(1983)
International Normalized Ratio in patients not on vitamin K antagonists
J Thromb Haemost
Vitamin K-dependent carboxylase: increased activity in a hypoprothrombinemia state
Arch Biochem Biophys
Vitamin K-dependent carboxylase: effect of detergent concentrations, vitamin K status, and added protein precursors on activity
Arch Biochem Biophys
Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid
Blood
The haemorrhagic disease of the new-born
Arch Pediatr
Vitamin K deficiency in the newborn: historical perspectives, diagnosis, and prevention
ISTH Pediatric/Perinatal Subcommittee International Society on Thrombosis and Haemostasis. Vitamin K deficiency bleeding (VKDB) in infancy
Thromb Haemost
Epidemiology of late onset haemorrhagic disease: a pooled data analysis
J Paediatr Child Health
Vitamin K metabolism
Subcell Biochem
On the prevention of hemorrhagic disease of the new-born by the administration of cow’s milk during the first two days of life
Acta Paediatr
Investigations into the cause of the physiological hypoprothrombinemia in newborn children IV. The vitamin K content of woman’s milk and cow’s milk
Acta Med Scand
Vitamin K in milk and infant formulas: determination and distribution of phylloquinone and menaquinone-4
Analyst
Menaquinone-4 in breast milk is derived from dietary phylloquinone
Brit J Nutr
Vitamin K1 content of maternal milk: influence of stage of lactation, lipid composition, and vitamin K1 supplements given to the mother
Pediatr Res
Vitamin K status of lactating mothers, human milk, and breast-feeding infants
Pediatrics
Four methods compared for measuring des-carboxy-prothrombin (PIVKA-II)
Clin Chem
Vitamin K prophylaxis for preterm infants: a randomized, controlled trial of 3 regimens
Pediatrics
Vitamin K in the newborn: influence of nutritional factors on acarboxy-prothrombin detectability and factor II and VII clotting activity
Eur J Pediatr
Plasma concentrations of vitamin K1 and PIVKA-II in bottle-fed and breast-fed infants with and without vitamin K prophylaxis at birth
Eur J Pediatr
Vitamin K deficiency in breast-fed infants at one month of age
J Pediatr Gastroenterol Nutr
The importance of menaquinones in human nutrition
Annu Rev Nutr
Relationship of milk intake and vitamin K supplementation to vitamin K status in newborns
Pediatrics
The second nation-wide survey in Japan of vitamin K deficiency in infancy
Eur J Pediatr
Vitamin K in infancy
Eur J Pediatr
Can 3 oral 2 mg doses of vitamin K effectively prevent late vitamin K deficiency bleeding?
Eur J Pediatr
Haemorrhagic disease of the newborn: a review of 127 cases
Ann Trop Paediatr
Hemorrhagic disease of the newborn. Breast feeding as a necessary factor in the pathogenesis
Am J Dis Child
Prevention of vitamin K deficiency bleeding: efficacy of different multiple oral dose schedules of vitamin K
Eur J Pediatr
Vitamin K deficiency bleeding in Great Britain and Ireland: British Paediatric Surveillance Unit Surveys, 1993–1994 and 2001–2002
Arch Dis Child
Developmental haemostasis. Impact for clinical haemostasis laboratories
Thromb Haemost
Routine coagulation tests in newborn and young infants
J Thromb Thrombolysis
Cited by (204)
Vitamin K Status and All-Cause Mortality: Is there a link?
2024, Journal of NutritionThe infant with rectal bleeding
2023, Paediatrics and Child Health (United Kingdom)Nutritional Toxicologic Pathology
2023, Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 3: Environmental Toxicologic Pathology and Major Toxicant ClassesVitamin K
2023, Encyclopedia of Human Nutrition: Volume 1-4, Fourth EditionEffects of continuity of maternal health services on immediate newborn care practices, Northwestern Ethiopia: multilevel and propensity score matching (PSM) modeling
2022, HeliyonCitation Excerpt :During pregnancy and breastfeeding, the newborns do not receive enough amount of vitamin K from their mothers [41]. As result, newborns are at risk of developing a rare condition known as vitamin K deficiency hemorrhage, which is potentially fatal [41, 42]. Hence, this study explored that vitamin K injection at birth is 56.7% which is extremely lower than evidence from Northwest Tigray (79.3%) [26] and Northeast Ethiopia (98.0%) [14].
Exclusively breastmilk-fed preterm infants are at high risk of developing subclinical vitamin K deficiency despite intramuscular prophylaxis at birth
2022, Journal of Thrombosis and Haemostasis